Multiple Sclerosis. Multiple sclerosis (MS), also known as
Conditions
Interventions
Intervention 1: Case group receives Imatinib 400 mg daily (PO). Intervention 2: Control group will receive Novanterone according to accepted guidelines.
Treatment - Drugs
Case group receives Imatinib 400 mg daily (PO)
Control group will receive Novanterone according to accepted guidelines
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: SPMS patients with relapse; EDSS between 3 and 5; age between 18 and 40 Exclusion criteria: History of other autoimmune disorder or chronic hematologic, renal, liver or infectious diseases; Pregnancy; lactation; History of HIV and Hepatitis; History of cancer especially breast tumor; History of recent herpes zoster infection; History of cytotoxic drugs consumption during recent three months; History of high dose corticosteroid during recent two months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical signs and symptoms. Timepoint: every one month. Method of measurement: Number of relapses during six months, EDSS changes.;Adverse effect. Timepoint: every one month. Method of measurement: biochemical test, clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of new plaques in MRI. Timepoint: six months. Method of measurement: Brain MRI with and without Gad. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohammad Hossein Harirchian
Tehran University of Medical Sciences
Outcome results
None listed